38
Participants
Start Date
May 14, 2014
Primary Completion Date
May 18, 2015
Study Completion Date
May 18, 2015
DX-2930
Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
Placebo
Participants will receive matching placebo subcutaneously.
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center, New York
Winthrop-University Hospital, Clinical Trials Center, Mineola
Jordan University Hospital, Amman
Penn State Hershey Medical Center, Hershey
Ospedale L. Sacco, Milan
Institute for Asthma & Allergy, PC, Chevy Chase
University of South Florida Asthma, Allergy or Immunology Clinical Research Unit, Tampa
UC Physicians Company, Cincinnati
Washington University School of Medicine, St Louis
AARA Research Center, Dallas
UC San Diego Health System - La Jolla, San Diego
Allergy & Asthma Clinical Research, Walnut Creek
Baker Allergy, Asthma and Dermatology Research Center, Lake Oswego
Massachusetts General Hospital Allergy Associates, Boston
Lead Sponsor
Shire
INDUSTRY